Get started
SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT)SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT)SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT)

SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT)

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0LC7 chart


Full chart

0LC7 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪7.43 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.032 USD
Net income (FY)
‪−164.57 M‬ USD
Revenue (FY)
‪9.94 M‬ USD
Shares float
‪16.89 M‬
Beta (1Y)
2.46

Employees


Employees (FY)
68
Change (1Y)
−49 −41.88%
Revenue / Employee (1Y)
‪146.12 K‬ USD
Net income / Employee (1Y)
‪−2.42 M‬ USD

About Syros Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Biotechnology
Headquarters
Cambridge
Website
syros.com
Founded
2011
FIGI
BBG00JVXHG98
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0LC7 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0LC7 is 0.278 USD — it has decreased by −1.23% in the past 24 hours. Watch SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) stocks are traded under the ticker 0LC7.
0LC7 stock has fallen by −26.31% compared to the previous week, the month change is a −86.18% fall, over the last year SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) has showed a −90.38% decrease.
We've gathered analysts' opinions on SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) future price: according to them, 0LC7 price has a max estimate of 20.00 USD and a min estimate of 1.00 USD. Watch 0LC7 chart and read a more detailed SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) stock forecast: see what analysts think of SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) and suggest that you do with its stocks.
0LC7 reached its all-time high on Jan 20, 2021 with the price of 151.900 USD, and its all-time low was 0.248 USD and was reached on Nov 15, 2024. View more price dynamics on 0LC7 chart.
See other stocks reaching their highest and lowest prices.
0LC7 stock is 11.54% volatile and has beta coefficient of 2.46. Track SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) stock price on the chart and check out the list of the most volatile stocks — is SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) there?
Today SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) has the market capitalization of ‪7.78 M‬, it has increased by 5.42% over the last week.
Yes, you can track SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) financials in yearly and quarterly reports right on TradingView.
SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
0LC7 earnings for the last quarter are −0.16 USD per share, whereas the estimation was −0.68 USD resulting in a 76.34% surprise. The estimated earnings for the next quarter are −0.69 USD per share. See more details about SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) earnings.
SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪360.00 K‬ USD. In the next quarter, revenue is expected to reach ‪450.00 K‬ USD.
0LC7 net income for the last quarter is ‪−6.40 M‬ USD, while the quarter before that showed ‪−23.33 M‬ USD of net income which accounts for 72.58% change. Track more SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) financial stats to get the full picture.
No, 0LC7 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 68.00 employees. See our rating of the largest employees — is SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) EBITDA is ‪−110.25 M‬ USD, and current EBITDA margin is ‪−1.25 K‬%. See more stats in SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) financial statements.
Like other stocks, 0LC7 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) stock shows the sell signal. See more of SYROS PHARMACEUTICALS INC COM USD0.001 (POST REV SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.